Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1998 Jan;82(1):39–42. doi: 10.1136/bjo.82.1.39

Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers

C Baudouin 1, C de Lunardo 1
PMCID: PMC1722345  PMID: 9536878

Abstract

AIM—A crossover, randomised double blind study was undertaken in 30 healthy volunteers, in order to compare the tolerance of 2% carteolol with and without preservative in short term use.
METHODS—Complete ophthalmic examinations were performed before and 30, 60, and 180 minutes after instillation of one drop of the solution, and after 3 days of preservative treatment. After a 5 day washout, the same examinations were done with the second drug.
RESULTS—Results showed good general tolerance for both formulations. No significant difference in subjective tolerance, corneal aesthesiometry, punctuate keratitis, Schirmer's test, intraocular pressure (IOP) decrease (about 25% in the two groups at 3 hours, 10% after 3 days of treatment), resting cardiac frequency, or blood pressure was observed. However, break up time was significantly reduced from baseline by preserved carteolol both at 3 hours (10.40 (5.9) seconds to 6.15 (3.9) seconds, p=0.001) and after 3 days (7.72 (5.5) seconds, p=0.04). Preservative free carteolol did not significantly change the break up time (baseline 9.08 (5.7) seconds; 3 hours = 7.88 (5.5) seconds, not significant; day 3 = 8.35 (5.8), non-significant).
CONCLUSIONS—These results confirm that carteolol is well tolerated, either with or without preservative. The preservative free group showed better stability of the tear film, without loss of effect on IOP. This difference, although mild in the healthy young subjects in the present study could be much more relevant in those patients treated long term, older patients, and/or those suffering from ocular surface disorders. In such instances, preservative free drugs could be of potential benefit to protect the lacrimal fluid integrity and corneoconjunctival surface.

 Keywords: glaucoma; carteolol; benzalkonium; preservatives; β blockers

Full Text

The Full Text of this article is available as a PDF (104.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anders N., Wollensak J. Okuläres Pseudopemphigoid nach topischer Medikamentenapplikation. Klin Monbl Augenheilkd. 1994 Aug;205(2):61–64. doi: 10.1055/s-2008-1045493. [DOI] [PubMed] [Google Scholar]
  2. Baudouin C., Garcher C., Haouat N., Bron A., Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994 Mar;101(3):454–460. doi: 10.1016/s0161-6420(94)31322-4. [DOI] [PubMed] [Google Scholar]
  3. Berlin I., Marcel P., Uzzan B., Millon D., Le Hoang P., Puech A. J. A single dose of three different ophthalmic beta-blockers antagonizes the chronotropic effect of isoproterenol in healthy volunteers. Clin Pharmacol Ther. 1987 Jun;41(6):622–626. doi: 10.1038/clpt.1987.85. [DOI] [PubMed] [Google Scholar]
  4. Brandt J. D., Wittpenn J. R., Katz L. J., Steinmann W. N., Spaeth G. L. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol. 1991 Sep 15;112(3):297–301. doi: 10.1016/s0002-9394(14)76730-3. [DOI] [PubMed] [Google Scholar]
  5. Broadway D. C., Grierson I., O'Brien C., Hitchings R. A. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994 Nov;112(11):1437–1445. doi: 10.1001/archopht.1994.01090230051020. [DOI] [PubMed] [Google Scholar]
  6. Broadway D. C., Grierson I., O'Brien C., Hitchings R. A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994 Nov;112(11):1446–1454. doi: 10.1001/archopht.1994.01090230060021. [DOI] [PubMed] [Google Scholar]
  7. Burstein N. L. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci. 1980 Mar;19(3):308–313. [PubMed] [Google Scholar]
  8. Burstein N. L. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci. 1980 Mar;19(3):308–313. [PubMed] [Google Scholar]
  9. Chrisp P., Sorkin E. M. Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension. Drugs Aging. 1992 Jan-Feb;2(1):58–77. doi: 10.2165/00002512-199202010-00007. [DOI] [PubMed] [Google Scholar]
  10. Denis P., Demailly P., Saraux H. Evaluation clinique du bétaxolol en suspension ophtalmique avec ou sans conservateur chez des patients glaucomateux ou hypertones. J Fr Ophtalmol. 1993;16(5):297–303. [PubMed] [Google Scholar]
  11. Duff G. R., Newcombe R. G. The 12-hour control of intraocular pressure on carteolol 2% twice daily. Br J Ophthalmol. 1988 Dec;72(12):890–891. doi: 10.1136/bjo.72.12.890. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kuppens E. V., de Jong C. A., Stolwijk T. R., de Keizer R. J., van Best J. A. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol. 1995 Apr;79(4):339–342. doi: 10.1136/bjo.79.4.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lavin M. J., Wormald R. P., Migdal C. S., Hitchings R. A. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990 Nov;108(11):1543–1548. doi: 10.1001/archopht.1990.01070130045027. [DOI] [PubMed] [Google Scholar]
  14. Marquardt R., Schubert T. Beeinflussung der Tränenfilmaufreisszeit (BUT) durch Betablocker-Augentropfen ohne Konservierungsstoffe. Klin Monbl Augenheilkd. 1991 Aug;199(2):75–78. doi: 10.1055/s-2008-1046051. [DOI] [PubMed] [Google Scholar]
  15. Mietz H., Niesen U., Krieglstein G. K. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol. 1994 Sep;232(9):561–565. doi: 10.1007/BF00182000. [DOI] [PubMed] [Google Scholar]
  16. Schwab I. R., Linberg J. V., Gioia V. M., Benson W. H., Chao G. M. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology. 1992 Feb;99(2):197–202. doi: 10.1016/s0161-6420(92)32001-9. [DOI] [PubMed] [Google Scholar]
  17. Sherwood M. B., Grierson I., Millar L., Hitchings R. A. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989 Mar;96(3):327–335. doi: 10.1016/s0161-6420(89)32888-0. [DOI] [PubMed] [Google Scholar]
  18. Williams D. E., Nguyen K. D., Shapourifar-Tehrani S., Kitada S., Lee D. A. Effects of timolol, betaxolol, and levobunolol on human tenon's fibroblasts in tissue culture. Invest Ophthalmol Vis Sci. 1992 Jun;33(7):2233–2241. [PubMed] [Google Scholar]
  19. Young T. L., Higginbotham E. J., Zou X. L., Farber M. D. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology. 1990 Nov;97(11):1423–1427. doi: 10.1016/s0161-6420(90)32392-8. [DOI] [PubMed] [Google Scholar]
  20. Zimmerman T. J. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol. 1993 Winter;9(4):373–384. doi: 10.1089/jop.1993.9.373. [DOI] [PubMed] [Google Scholar]
  21. de Jong C., Stolwijk T., Kuppens E., de Keizer R., van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994 Apr;232(4):221–224. doi: 10.1007/BF00184009. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES